Virax Biolabs rises on COVID, influenza rapid test launch deal

Cosmos Health

07/02/2023 16:52

** Shares of biotech company Virax Biolabs Group Ltd
 VRAX.O  rise 8.5% to $0.89
    ** VRAX signs purchase order with Cosmos Health Inc  COSM.O 
to launch and market COVID-19 and influenza antigen combo rapid
detection kits
    ** The rapid test is a single-use test kit intended for
qualitative detection of influenza A and B viral antigens and
COVID-19 antigen from nasal swab specimens - VRAX
    ** VRAX stock up 21.8% so far in 2023
 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))